The Blood and Marrow Transplant (BMT) Program at Roswell Park Cancer Institute
The Blood and Marrow Transplant (BMT) program is dedicated to providing outstanding clinical care and conducting clinical trials related to novel approaches to BMT.
- There are 153 Allogeneic BMT Centers who report outcomes data to the National Marrow Donor Program (NMDP)
- There are 13/153 (8%) Allogeneic BMT Centers with survival outcomes that are statistically superior to their expected outcomes
- RPCI is one of these 13 Allogeneic BMT Centers
Read more about these outcomes.
The BMT Program treats selected patients with hematologic diseases including:
- Acute and Chronic Leukemia
- Aplastic Anemia
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndrome and Myeloproliferative Disorders
- Selected solid tumors
The BMT Program
The Roswell Park Cancer Institute (RPCI) Blood and Marrow Transplant (BMT) Program was established in 1991 and is certified by the National Marrow Donor Program as a Transplant, Collection and Apheresis Center.
The BMT team, under the direction of Philip McCarthy, MD offers both autologous (self-donated) and allogeneic (requiring a related or unrelated donor) transplantation of peripheral blood, bone marrow or cord blood. The RPCI program can offer BMT to patients aged 4 to 75 years.
The BMT program at RPCI offers a wide range of specialized transplant-related services including:
- Cord blood transplant
- Reduced intensity conditioning regimens
- Unrelated donor BMT
- Case management
- Quality assurance program
- A dedicated on-site outpatient BMT clinic in the same building as the inpatient unit
- On-site blood and marrow collection and processing
A unique aspect of our program is the presence of a clinical epidemiologist who monitors all BMT patient outcomes and oversees the BMT database. This attention to patient outcomes allows the program to make adjustments in clinical services to optimize patient care.
Since 2002, the program has had been certified through the Foundation for the Accreditation of Cellular Therapy (FACT). It emphasizes clinical trial development including investigator-initiated as well as cooperative group trials. The program continues to emphasize excellence in clinical care and patient outcomes.